Latacomp

Timolol maleate and latanoprost, the active ingredients in Latacomp, are a beta‑blocker and a prostaglandin analog presented as ophthalmic eye drops for ocular administration. The combination reduces intra‑ocular pressure in patients with primary open‑angle glaucoma and ocular hypertension, offering a dual mechanism of action.

GNH USA supplies Latacomp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with European Union marketing authorisation requirements and is manufactured under GMP conditions, ensuring consistent potency and safety for global distribution.

Latacomp, a combination antiglaucoma agent, is used to manage conditions characterized by elevated intra‑ocular pressure.

Primary open‑angle glaucoma: lowers IOP to slow disease progression. Ocular hypertension: reduces IOP to prevent conversion to glaucoma. Glaucoma (any type): provides IOP reduction when pressure‑lowering therapy is required.

Adverse reactions may occur with ocular use of Latacomp.

Common Side Effects: - Eye irritation or burning sensation. - Blurred vision shortly after instillation. - Redness of the conjunctiva. - Itching or mild allergic response. - Dry eye sensation. - Foreign body feeling in the eye.

Serious or Rare Side Effects: - Severe allergic reaction with swelling or hives. - Persistent eye pain or corneal edema. - Sudden loss of vision. - Unexpected increase in intra‑ocular pressure. - Systemic beta‑blocker effects such as bradycardia or hypotension. - Worsening of asthma or COPD symptoms.

Use of Latacomp requires careful assessment of patient history and monitoring.

Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. Breastfeeding: caution advised; the drug may be excreted in breast milk. Systemic β‑blocker contraindications: avoid in patients with asthma, COPD, severe bradycardia, or heart block. Contact lens wearers: remove lenses before instilling drops and wait at least 15 minutes before reinserting. Monitor intra‑ocular pressure: assess response after initiation and adjust therapy as needed. Store at room temperature: keep in the original container, protect from light and moisture.

Latacomp may interact with other medications affecting ocular pressure or systemic β‑adrenergic activity.

Major Interactions (Avoid): - Concomitant use of other non‑selective β‑blockers (e.g., propranolol) may cause additive systemic β‑blockade. - Simultaneous administration of other prostaglandin analogs can increase risk of ocular inflammation.

Moderate Interactions (Monitor Closely): - Topical or systemic adrenergic agonists (e.g., epinephrine) may diminish timolol's IOP‑lowering effect. - Carbonic anhydrase inhibitors (e.g., dorzolamide) may produce additive IOP reduction; monitor pressure closely. - Systemic antihypertensives may enhance timolol‑induced bradycardia. - NSAID eye drops may interfere with latanoprost absorption. - Anticholinergic agents may affect tear film stability, influencing tolerability.